DE60323339D1 - Monoester und asymmetrisch substituierte diester prodrugs der dopamin-d1-rezeptor-agonisten - Google Patents

Monoester und asymmetrisch substituierte diester prodrugs der dopamin-d1-rezeptor-agonisten

Info

Publication number
DE60323339D1
DE60323339D1 DE60323339T DE60323339T DE60323339D1 DE 60323339 D1 DE60323339 D1 DE 60323339D1 DE 60323339 T DE60323339 T DE 60323339T DE 60323339 T DE60323339 T DE 60323339T DE 60323339 D1 DE60323339 D1 DE 60323339D1
Authority
DE
Germany
Prior art keywords
dopamine
monoester
asymmetrically substituted
receptor agonists
substituted diester
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60323339T
Other languages
English (en)
Inventor
Durk Dijkstra
Hakan Wikstrom
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Darpharma Inc
Original Assignee
Darpharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0200478A external-priority patent/SE0200478D0/xx
Priority claimed from SE0200474A external-priority patent/SE0200474D0/xx
Application filed by Darpharma Inc filed Critical Darpharma Inc
Application granted granted Critical
Publication of DE60323339D1 publication Critical patent/DE60323339D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/18—Ring systems of four or more rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
DE60323339T 2002-02-15 2003-02-14 Monoester und asymmetrisch substituierte diester prodrugs der dopamin-d1-rezeptor-agonisten Expired - Fee Related DE60323339D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0200478A SE0200478D0 (sv) 2002-02-15 2002-02-15 Mono-ester and asymmetrically substituted di-ester pro-drugs of the dopamine D1 receptor agonist A-86929
SE0200474A SE0200474D0 (sv) 2002-02-17 2002-02-17 Mono-ester and asymmetrically substituted di-ester pro-drugs of the dopamine D1 receptor agonists Dihydrexidine and Dinapsoline
PCT/US2003/004592 WO2003070245A1 (en) 2002-02-15 2003-02-14 Mono-ester and asymmetrically substituted di-ester pro-drugs of the dopamine d1 receptor agonists

Publications (1)

Publication Number Publication Date
DE60323339D1 true DE60323339D1 (de) 2008-10-16

Family

ID=27759833

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60323339T Expired - Fee Related DE60323339D1 (de) 2002-02-15 2003-02-14 Monoester und asymmetrisch substituierte diester prodrugs der dopamin-d1-rezeptor-agonisten

Country Status (11)

Country Link
US (1) US7220754B2 (de)
EP (1) EP1480647B1 (de)
JP (1) JP2005526728A (de)
AT (1) ATE406896T1 (de)
AU (1) AU2003217430B2 (de)
CA (1) CA2476115A1 (de)
DE (1) DE60323339D1 (de)
DK (1) DK1480647T3 (de)
ES (1) ES2314189T3 (de)
NO (1) NO20043634L (de)
WO (1) WO2003070245A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9046537B2 (en) 2003-09-22 2015-06-02 Enzo Biochem, Inc. Method for treating inflammation by administering a compound which binds LDL-receptor-related protein (LRP) ligand binding domain
JP2007516292A (ja) * 2003-12-23 2007-06-21 ダーファーマ，インコーポレイテッド ドーパミン受容体結合化合物の共投与
US9052324B2 (en) 2004-05-19 2015-06-09 Enzo Biochem, Inc. Compounds and assays for controlling Wnt activity
US8596306B2 (en) * 2005-10-27 2013-12-03 Synthetic Gas Solutions, Llc Perfluorocarbon gas insufflation
EP2010541A2 (de) * 2006-02-21 2009-01-07 Purdue Research Foundation Übertragene chromenoisochinoline, synthese und anwendungsverfahren
EP2421862B1 (de) 2009-04-21 2014-06-11 Purdue Research Foundation Octahydrobenzoisochinolinmodulatoren von dopaminrezeptoren und ihre verwendung
US20150291625A1 (en) * 2012-11-08 2015-10-15 Pfizer Inc. Heteroaromatic Compounds and their Use as Dopamine D1 Ligands

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4340600A (en) * 1980-05-22 1982-07-20 Smithkline Corporation Renal dilating methods and compositions using 4-(3,4-dihydroxyphenyl)-1,2,3,4-tetrahydroisoquinolines
US4282227A (en) * 1980-05-22 1981-08-04 Smithkline Corporation Renal vasodilating 3,4-dihydroxyphenyltetrahydrothienopyridines
JPH02138A (ja) * 1987-09-18 1990-01-05 Banyu Pharmaceut Co Ltd Ｌ‐ドーパ誘導体
US5047536A (en) * 1989-03-17 1991-09-10 Purdue Research Foundation Hexahydrobenzo(A)phenanthridine compounds
IE912999A1 (en) 1990-09-07 1992-03-11 Abbott Lab Phenanthridine compounds
KR100292928B1 (ko) * 1992-05-26 2001-11-05 프란시스 제이 메이어 치환된헥사하이드로벤조페난트리딘
ATE233765T1 (de) * 1993-04-06 2003-03-15 Abbott Lab Tetracyclische verbindungen als dopamin-agonisten
JPH10502923A (ja) * 1994-07-15 1998-03-17 パーデュー・リサーチ・ファンデーション ジヒドレキシジンおよびその置換類似体の光学活性異性体
WO1997006799A1 (en) * 1995-08-18 1997-02-27 Purdue Research Foundation Novel fused isoquinolines as dopamine receptor ligands

Also Published As

Publication number Publication date
DK1480647T3 (da) 2009-01-26
ES2314189T3 (es) 2009-03-16
JP2005526728A (ja) 2005-09-08
NO20043634L (no) 2004-11-11
ATE406896T1 (de) 2008-09-15
WO2003070245B1 (en) 2004-05-27
US7220754B2 (en) 2007-05-22
US20050096469A1 (en) 2005-05-05
AU2003217430B2 (en) 2008-10-23
EP1480647B1 (de) 2008-09-03
EP1480647A4 (de) 2005-07-13
CA2476115A1 (en) 2003-08-28
WO2003070245A1 (en) 2003-08-28
EP1480647A1 (de) 2004-12-01
AU2003217430A1 (en) 2003-09-09

Similar Documents

Publication Publication Date Title
HRP20050191B1 (hr) Novi derivati benzoimidazola korisni kao antiproliferativna sredstva
NZ514409A (en) C7 ester substituted taxanes as antitumor agents
CR9587A (es) Derivados de piridazina
CY1112941T1 (el) Δικυκλικοι αναστολεις της μεκ
AR056873A1 (es) Derivados de pirazolopirimidinas como inhibidores de quinasa dependientes de ciclina, composiciones farmaceuticas
DE602004008098D1 (de) Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren
AR021482A1 (es) Compuestos de 4-carboxiamino-1,2,3,4-tetrahidroquinolinas, composiciones farmaceuticas, kit, y uso de los mismos.
UY27633A1 (es) Nuevos ésteres de ácido fluoreno-carbox ílicos, procedimientos para su preparación así como su utilización en calidad de medicamentos
PA8621501A1 (es) Intermediarios de quinolina como inhibidores de receptores de tirosina quinasas y la síntesis de los mismos
ECSP045182A (es) Procedimiento para la preparación de ésteres de escopina
GT200100196A (es) Nuevos tiadiazoles y oxadiazoles y su uso como inhibidores de fosfodiesterasa-7.
NO20061126L (no) Aminopyroner og deres anvendelse som ATM-inhibitorer
MX2010007023A (es) Agonistas del receptor glucocorticoide sustituido de c20-c21.
ECSP088229A (es) Derivados de pirazolona como inhibidores de 11-beta hsd1
BRPI0506477A (pt) compostos farmaceuticamente úteis e inovadores
ATE450499T1 (de) Durch enzyme spaltbare prodrugs von substituierten stickstoff-lost-derivaten
DE60323339D1 (de) Monoester und asymmetrisch substituierte diester prodrugs der dopamin-d1-rezeptor-agonisten
UY30787A1 (es) "inhibidores benzoimidazolicos de trpv1"
BRPI0409105A (pt) análogos de quinobenzoxazina substituìdos
MX9307608A (es) Inhibidores de la liberacion de la citocina y antagonistas de la il-1,procedimiento para su preparacion y composiciones farmaceuticas que loscontienen.
AR004512A1 (es) Derivados de benzotiazolona, procedimientos para su preparacion, compuestos intermediarios utiles para llevar a cabo dicho procedimiento ycomposiciones farmaceuticas que comprenden dichos derivados
DE60002733D1 (de) Diester prodrugs von decahydroischinoline-3-carbonsäure
WO2004091627A3 (en) Heterocyclic substituted 1,4-dihydro-4-oxo-1,8-naphthpyridine analogs
ATE371644T1 (de) Neues alkaloidderivat und dieses enthaltende pharmazeutische zusammensetzung
TW200724168A (en) Pharmaceutical compositions

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee